Gastrointestinal: Pembrolizumab-induced gastric ulcer occurring as an immune-related adverse event. Terasaki K, Ueno A, Mizuno C, Shima T, et al. J Gastroenterol Hepatol 2022 Feb 9. doi: 10.1111/jgh.15788.

Read + Share

Amedeo Smart

Independent Medical Education

Terasaki K, Ueno A, Mizuno C, Shima T, et al. Gastrointestinal: Pembrolizumab-induced gastric ulcer occurring as an immune-related adverse event. J Gastroenterol Hepatol 2022 Feb 9. doi: 10.1111/jgh.15788.
PMID: 35141946